About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Cilostazol for Prevention of Recurrent Stroke Trial

NCT07174414·1 site·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

Stanford University

With

National Institute of Neurological Disorders and Stroke (NINDS)
Yale University
University of Cincinnati
Medical University of South Carolina

Age

40–any

Sex

ALL

Healthy volunteers

Not accepted

You may be eligible if

Diagnosis of stroke or mini-stroke (also called TIA) within the last 180 days
Currently taking aspirin or clopidogrel (not both) to prevent another stroke

You may not be if

Had a spontaneous brain bleed within the last 2 years.
Moderate to severe heart failure.
Life expectancy is less than 6 months.

The record

StatusNot yet recruiting

PhasePhase 3

Taking part2,000

StartedAug 2026

UpdatedSep 16, 2025

Conditions

Stroke Recurrence Myocardial Infarction Vascular Death Ischemic Stroke TIA (Transient Ischemic Attack)+2

Where1

Stanford University
Stanford, California, United States

Clareo Health | Cilostazol for Prevention of Recurrent Stroke Trial